Blood beta-amyloid and tau in down syndrome

A comparison with Alzheimer's disease

Ni Chung Lee, Shieh Yueh Yang, Jen Jie Chieh, Po Tsang Huang, Lih Maan Chang, Yen Nan Chiu, Ai Chiu Huang, Yin Hsiu Chien, Wuh Liang Hwu, Ming Jang Chiu

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Background: Changes in β-amyloids (Aβ) and tau proteins have been noted in patients with Alzheimer's disease (AD) and patients with both Down syndrome (DS) and AD. However, reports of changes in the early stage of regression, such as behavioral and psychological symptoms of dementia (BPSD), in DS are sparse. Methods: Seventy-eight controls, 62 patients with AD, 35 with DS and 16 with DS with degeneration (DS_D), including 9 with BPSD and 7 with dementia, were enrolled. The levels of β-amyloids 40 and 42 (Aβ-40, Aβ-42) and tau protein in the blood were analyzed using immunomagnetic reduction (IMR). The Adaptive Behavior Dementia Questionnaire (ABDQ) was used to evaluate the clinical status of the degeneration. Results: The Aβ-40 and tau levels were higher and the Aβ-42 level and Aβ-42/Aβ-40 ratio were lower in DS than in the controls (all p < 0.001). Decreased Aβ-40 and increased Aβ-42 levels and Aβ-42/40 ratios were observed in DS_D compared with DS without degeneration (all p < 0.001). The ABDQ score was negatively correlated with the Aβ-40 level (ρ = -0.556) and the tau protein level (ρ = -0.410) and positively associated with the Aβ-42 level (ρ = 0.621) and the Aβ-42/40 ratio (ρ = 0.544; all p < 0.05). Conclusions: The Aβ-40 and Aβ-42 levels and the Aβ-42/Aβ-40 ratio are considered possible biomarkers for the early detection of degeneration in DS. The elevated Aβ-40 and tau levels in DS may indicate early neurodegeneration. The increased Aβ-42 in DS_D may reflect the neurotoxicity of Aβ-42. The paradox of the tau decreases in DS_D could be explained by a burnout phenomenon during long-term neurodegeneration. The different patterns of the plasma beta amyloids and tau protein may imply a different pathogenesis between DS with degeneration and AD in the general population, in spite of their common key pathological features.

Original languageEnglish
Article number316
JournalFrontiers in Aging Neuroscience
Volume8
Issue numberJAN
DOIs
Publication statusPublished - 2017 Jan 17

Fingerprint

Down Syndrome
Amyloid
Alzheimer Disease
tau Proteins
Dementia
Behavioral Symptoms
Psychological Adaptation
Psychology
Serum Amyloid A Protein
Amyloid beta-Peptides
Blood Proteins
Biomarkers

Keywords

  • Alzheimer's disease
  • Behavioral and psychological symptoms of dementia
  • Dementia
  • Down syndrome
  • Tau protein
  • β-amyloids

ASJC Scopus subject areas

  • Ageing
  • Cognitive Neuroscience

Cite this

Blood beta-amyloid and tau in down syndrome : A comparison with Alzheimer's disease. / Lee, Ni Chung; Yang, Shieh Yueh; Chieh, Jen Jie; Huang, Po Tsang; Chang, Lih Maan; Chiu, Yen Nan; Huang, Ai Chiu; Chien, Yin Hsiu; Hwu, Wuh Liang; Chiu, Ming Jang.

In: Frontiers in Aging Neuroscience, Vol. 8, No. JAN, 316, 17.01.2017.

Research output: Contribution to journalArticle

Lee, NC, Yang, SY, Chieh, JJ, Huang, PT, Chang, LM, Chiu, YN, Huang, AC, Chien, YH, Hwu, WL & Chiu, MJ 2017, 'Blood beta-amyloid and tau in down syndrome: A comparison with Alzheimer's disease', Frontiers in Aging Neuroscience, vol. 8, no. JAN, 316. https://doi.org/10.3389/fnagi.2016.00316
Lee, Ni Chung ; Yang, Shieh Yueh ; Chieh, Jen Jie ; Huang, Po Tsang ; Chang, Lih Maan ; Chiu, Yen Nan ; Huang, Ai Chiu ; Chien, Yin Hsiu ; Hwu, Wuh Liang ; Chiu, Ming Jang. / Blood beta-amyloid and tau in down syndrome : A comparison with Alzheimer's disease. In: Frontiers in Aging Neuroscience. 2017 ; Vol. 8, No. JAN.
@article{d9ae8cfb6d674038935d5fb91e1603f1,
title = "Blood beta-amyloid and tau in down syndrome: A comparison with Alzheimer's disease",
abstract = "Background: Changes in β-amyloids (Aβ) and tau proteins have been noted in patients with Alzheimer's disease (AD) and patients with both Down syndrome (DS) and AD. However, reports of changes in the early stage of regression, such as behavioral and psychological symptoms of dementia (BPSD), in DS are sparse. Methods: Seventy-eight controls, 62 patients with AD, 35 with DS and 16 with DS with degeneration (DS_D), including 9 with BPSD and 7 with dementia, were enrolled. The levels of β-amyloids 40 and 42 (Aβ-40, Aβ-42) and tau protein in the blood were analyzed using immunomagnetic reduction (IMR). The Adaptive Behavior Dementia Questionnaire (ABDQ) was used to evaluate the clinical status of the degeneration. Results: The Aβ-40 and tau levels were higher and the Aβ-42 level and Aβ-42/Aβ-40 ratio were lower in DS than in the controls (all p < 0.001). Decreased Aβ-40 and increased Aβ-42 levels and Aβ-42/40 ratios were observed in DS_D compared with DS without degeneration (all p < 0.001). The ABDQ score was negatively correlated with the Aβ-40 level (ρ = -0.556) and the tau protein level (ρ = -0.410) and positively associated with the Aβ-42 level (ρ = 0.621) and the Aβ-42/40 ratio (ρ = 0.544; all p < 0.05). Conclusions: The Aβ-40 and Aβ-42 levels and the Aβ-42/Aβ-40 ratio are considered possible biomarkers for the early detection of degeneration in DS. The elevated Aβ-40 and tau levels in DS may indicate early neurodegeneration. The increased Aβ-42 in DS_D may reflect the neurotoxicity of Aβ-42. The paradox of the tau decreases in DS_D could be explained by a burnout phenomenon during long-term neurodegeneration. The different patterns of the plasma beta amyloids and tau protein may imply a different pathogenesis between DS with degeneration and AD in the general population, in spite of their common key pathological features.",
keywords = "Alzheimer's disease, Behavioral and psychological symptoms of dementia, Dementia, Down syndrome, Tau protein, β-amyloids",
author = "Lee, {Ni Chung} and Yang, {Shieh Yueh} and Chieh, {Jen Jie} and Huang, {Po Tsang} and Chang, {Lih Maan} and Chiu, {Yen Nan} and Huang, {Ai Chiu} and Chien, {Yin Hsiu} and Hwu, {Wuh Liang} and Chiu, {Ming Jang}",
year = "2017",
month = "1",
day = "17",
doi = "10.3389/fnagi.2016.00316",
language = "English",
volume = "8",
journal = "Frontiers in Aging Neuroscience",
issn = "1663-4365",
publisher = "Frontiers Research Foundation",
number = "JAN",

}

TY - JOUR

T1 - Blood beta-amyloid and tau in down syndrome

T2 - A comparison with Alzheimer's disease

AU - Lee, Ni Chung

AU - Yang, Shieh Yueh

AU - Chieh, Jen Jie

AU - Huang, Po Tsang

AU - Chang, Lih Maan

AU - Chiu, Yen Nan

AU - Huang, Ai Chiu

AU - Chien, Yin Hsiu

AU - Hwu, Wuh Liang

AU - Chiu, Ming Jang

PY - 2017/1/17

Y1 - 2017/1/17

N2 - Background: Changes in β-amyloids (Aβ) and tau proteins have been noted in patients with Alzheimer's disease (AD) and patients with both Down syndrome (DS) and AD. However, reports of changes in the early stage of regression, such as behavioral and psychological symptoms of dementia (BPSD), in DS are sparse. Methods: Seventy-eight controls, 62 patients with AD, 35 with DS and 16 with DS with degeneration (DS_D), including 9 with BPSD and 7 with dementia, were enrolled. The levels of β-amyloids 40 and 42 (Aβ-40, Aβ-42) and tau protein in the blood were analyzed using immunomagnetic reduction (IMR). The Adaptive Behavior Dementia Questionnaire (ABDQ) was used to evaluate the clinical status of the degeneration. Results: The Aβ-40 and tau levels were higher and the Aβ-42 level and Aβ-42/Aβ-40 ratio were lower in DS than in the controls (all p < 0.001). Decreased Aβ-40 and increased Aβ-42 levels and Aβ-42/40 ratios were observed in DS_D compared with DS without degeneration (all p < 0.001). The ABDQ score was negatively correlated with the Aβ-40 level (ρ = -0.556) and the tau protein level (ρ = -0.410) and positively associated with the Aβ-42 level (ρ = 0.621) and the Aβ-42/40 ratio (ρ = 0.544; all p < 0.05). Conclusions: The Aβ-40 and Aβ-42 levels and the Aβ-42/Aβ-40 ratio are considered possible biomarkers for the early detection of degeneration in DS. The elevated Aβ-40 and tau levels in DS may indicate early neurodegeneration. The increased Aβ-42 in DS_D may reflect the neurotoxicity of Aβ-42. The paradox of the tau decreases in DS_D could be explained by a burnout phenomenon during long-term neurodegeneration. The different patterns of the plasma beta amyloids and tau protein may imply a different pathogenesis between DS with degeneration and AD in the general population, in spite of their common key pathological features.

AB - Background: Changes in β-amyloids (Aβ) and tau proteins have been noted in patients with Alzheimer's disease (AD) and patients with both Down syndrome (DS) and AD. However, reports of changes in the early stage of regression, such as behavioral and psychological symptoms of dementia (BPSD), in DS are sparse. Methods: Seventy-eight controls, 62 patients with AD, 35 with DS and 16 with DS with degeneration (DS_D), including 9 with BPSD and 7 with dementia, were enrolled. The levels of β-amyloids 40 and 42 (Aβ-40, Aβ-42) and tau protein in the blood were analyzed using immunomagnetic reduction (IMR). The Adaptive Behavior Dementia Questionnaire (ABDQ) was used to evaluate the clinical status of the degeneration. Results: The Aβ-40 and tau levels were higher and the Aβ-42 level and Aβ-42/Aβ-40 ratio were lower in DS than in the controls (all p < 0.001). Decreased Aβ-40 and increased Aβ-42 levels and Aβ-42/40 ratios were observed in DS_D compared with DS without degeneration (all p < 0.001). The ABDQ score was negatively correlated with the Aβ-40 level (ρ = -0.556) and the tau protein level (ρ = -0.410) and positively associated with the Aβ-42 level (ρ = 0.621) and the Aβ-42/40 ratio (ρ = 0.544; all p < 0.05). Conclusions: The Aβ-40 and Aβ-42 levels and the Aβ-42/Aβ-40 ratio are considered possible biomarkers for the early detection of degeneration in DS. The elevated Aβ-40 and tau levels in DS may indicate early neurodegeneration. The increased Aβ-42 in DS_D may reflect the neurotoxicity of Aβ-42. The paradox of the tau decreases in DS_D could be explained by a burnout phenomenon during long-term neurodegeneration. The different patterns of the plasma beta amyloids and tau protein may imply a different pathogenesis between DS with degeneration and AD in the general population, in spite of their common key pathological features.

KW - Alzheimer's disease

KW - Behavioral and psychological symptoms of dementia

KW - Dementia

KW - Down syndrome

KW - Tau protein

KW - β-amyloids

UR - http://www.scopus.com/inward/record.url?scp=85012110510&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85012110510&partnerID=8YFLogxK

U2 - 10.3389/fnagi.2016.00316

DO - 10.3389/fnagi.2016.00316

M3 - Article

VL - 8

JO - Frontiers in Aging Neuroscience

JF - Frontiers in Aging Neuroscience

SN - 1663-4365

IS - JAN

M1 - 316

ER -